Drug Profile
HIV gp160 vaccine - Intellivax
Latest Information Update: 18 Jan 2008
Price :
$50
*
At a glance
- Originator Intellivax
- Class AIDS vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued HIV infections
Most Recent Events
- 16 Apr 2003 No development reported - Preclinical for HIV infections treatment in Canada (unspecified route)
- 05 Jun 2001 Intellivax has been acquired by ID Biomedical Corporation
- 03 Nov 1999 New profile